Global Gastrointestinal Bleeding Treatment Market Share Is Expected To Grow At A CAGR Of 4.56% By 2030

11-Jan-2023 | Facts and Factors

According to Facts and Factors, the global gastrointestinal bleeding treatment market size was worth around USD 732 million in 2021 and is predicted to grow to around USD 1092 million by 2030 with a compound annual growth rate (CAGR) of roughly 4.56% between 2022 and 2030.

Gastrointestinal bleeding or GI bleeding is a symptom associated with different medical conditions and refers to bleeding that starts from the gastrointestinal (GI) tract. Although bleeding may originate at any site along the tract, it is mainly divided into two sections; upper GI bleeding and lower GI bleeding. The former includes sections like the stomach, esophagus, and the initial part of the small intestine.

Browse the full “Gastrointestinal Bleeding Treatment Market Size, Share, Growth Analysis Report By Gastrointestinal (GI) Tract Division (Lower GI and Upper GI), By Product (Closure Devices and Endoscopic Hemostatic Devices), and By Region - Global and Regional Industry Insights, Overview, Comprehensive Analysis, Trends, Statistical Research, Market Intelligence, Historical Data and Forecast 2022 – 2030" report at https://www.fnfresearch.com/gastrointestinal-bleeding-treatment-market

Lower GI bleeding occurs in the rest of the part of the small intestine, bowels or large intestine, rectum, and anus. In certain cases, GI bleeding can be so less that it can be detected only when checked in laboratory settings for instance fecal occult blood test. Other more evident or common symptoms of GI bleeding include tarry or dark stools, vomiting blood, large amounts of blood passing through the rectum, or small amounts of blood observed on toilet paper, in the toilet bowl, or streaks on feces.

In case the quantity progresses to large amounts, it can lead to serious conditions while small amounts of bleeding over time is also significantly dangerous as they may cause anemia. Different therapies can be used to treat the symptom once it is diagnosed.

The global gastrointestinal bleeding treatment market is projected to grow owing to the growing cases of peptic ulcers, one of the leading causes of GI bleeding. Peptic ulcers develop on the outside of the stomach lining and the most common symptom in the case of peptic ulcers is stomach ache. Peptic ulcers are induced by infection due to the bacterium Helicobacter pylori or prolonged use of anti-inflammatory drugs like ibuprofen or naproxen sodium.

Spicy food and stress may not induce the condition but can worsen the infection. Studies have indicated that one in every 10 people contracts the disease at a certain point. The global market may generate higher growth due to the growing investments by private and public healthcare agencies to encourage research & development in the treatment of GI bleeding.

One of the key growth restraints in the global market is the delayed diagnosis of the condition. In mild cases, since there are no obvious symptoms, the patient might not be aware of GI bleeding if the blood quantity is low. Only when the symptom becomes obvious, the patient may go for the necessary treatment. Delayed diagnosis can have a severe impact on overall health but simultaneously it is almost impossible to diagnose the condition in its early stage until the bleeding becomes more obvious.

The increasing cases of stomach cancer may cause further growth while clearing the blood clot and blood remains a challenge in the market

Segmental Overview

The global gastrointestinal bleeding treatment market is segmented based on gastrointestinal (GI) tract division, product, and region

Based on gastrointestinal (GI) tract division, the global market segments are lower GI and upper GI with the latter leading the segmental growth in 2021 due to the high prevalence of the condition. One of the major reasons for upper GI tract bleeding is peptic ulcer. These are sores that originate in the inner lining of the stomach along with the upper portion of the small intestine. The sores can be caused due to stomach lining getting damaged because of stomach acid, consumption of anti-inflammatory drugs, or bacteria. The chances of a person suffering from upper GI bleeding is 70% whereas the risk percentage for lower GI bleeding is around 30%.

Based on product, the global market divisions are closure devices and endoscopic hemostatic devices with the latter leading the global market growth in the previous year and the same trend projected for the coming years. Endoscopic hemostatic is one of the most common methods of treating gastrointestinal bleeding. The procedure is critical for managing GI hemorrhage and for preventing GI bleeding during highly risky endoscopic processes. A recent study concluded the success rate of endoscopic treatment for treating peptic ulcers was around 94%.

Regional Overview 

North America is projected to lead the global gastrointestinal bleeding treatment market due to the growing cases of GI bleeding influenced by various other diseases. The increasing rate of entry of new medical providers could help the global market grow further. Crohn’s disease is another leading cause of GI bleeding and the European (EU) population is highly prone to the medical condition.

As per an estimate, the prevalence rate in the EU is around 2 to 213 cases per 100,000. It is most common in the UK and Western Europe. Growth in Asia-Pacific will be largely attributed to the growing investments in the healthcare sector and increasing awareness about the condition. The rise in medical care accessibility could also help boost regional growth.

Report Scope

Competitive Landscape

The global gastrointestinal bleeding treatment market is led by players like Ovesco Endoscopy AG., CONMED Corporation, Cook Medical, Boston Scientific Corporation, Olympus Corporation, and US Medical Innovations.

Recent Developments:

• In September 2022, the US Food and Drugs Administration (FDA) cleared Nexpowder endoscopic hemostasis system
• In February 2021, the US DFA approved EndoClot® Polysaccharide Hemostatic System (EndoClot® PHS), which is claimed to stop bleeding reliably and rapidly

The global gastrointestinal bleeding treatment market is segmented as follows:

By Gastrointestinal (GI) Tract Division 

• Lower GI
• Upper GI

By Product 

• Closure Devices
• Endoscopic Hemostatic Devices

By Region

• North America
  • The U.S.
  • Canada
  • Mexico
• Europe
  • France
  • The UK
  • Spain
  • Germany
  • Italy
  • Nordic Countries
    • Denmark
    • Sweden
    • Norway
  • Benelux Union
    • Belgium
    • The Netherlands
    • Luxembourg
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Southeast Asia
    • Indonesia
    • Thailand
    • Malaysia
    • Singapore
    • Rest of Southeast Asia
  • Rest of Asia Pacific
• The Middle East & Africa
  • Saudi Arabia
  • UAE
  • Egypt
  • South Africa
  • Rest of the Middle East & Africa
• Latin America
  • Brazil
  • Argentina
  • Rest of Latin America

About Us:

Facts & Factors is a leading market research organization offering industry expertise and scrupulous consulting services to clients for their business development. The reports and services offered by Facts and Factors are used by prestigious academic institutions, start-ups, and companies globally to measure and understand the changing international and regional business backgrounds. Our client’s/customer’s conviction on our solutions and services has pushed us in delivering always the best. Our advanced research solutions have helped them in appropriate decision-making and guidance for strategies to expand their business.

Contact Us:
Facts & Factors
A 2108, Sargam,
Nanded City,
Sinhagad Road,
Pune 411041, India
USA: +1 (347) 690-0211
Email: [email protected]
Web: https://www.fnfresearch.com